Free Trial

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's What Happened

Autolus Therapeutics logo with Medical background

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $2.41, but opened at $2.57. Autolus Therapeutics shares last traded at $2.54, with a volume of 305,366 shares changing hands.

Analyst Ratings Changes

AUTL has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday. Truist Financial reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $9.32.

Check Out Our Latest Report on Autolus Therapeutics

Autolus Therapeutics Price Performance

The firm's 50-day moving average is $2.12 and its 200 day moving average is $1.89. The stock has a market cap of $706.60 million, a price-to-earnings ratio of -3.02 and a beta of 1.81.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. On average, sell-side analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Forefront Wealth Management Inc. acquired a new stake in shares of Autolus Therapeutics in the second quarter worth $61,000. Avanza Fonder AB increased its position in shares of Autolus Therapeutics by 151.6% in the second quarter. Avanza Fonder AB now owns 53,522 shares of the company's stock worth $122,000 after acquiring an additional 32,246 shares in the last quarter. Atle Fund Management AB increased its position in shares of Autolus Therapeutics by 130.5% in the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock worth $2,520,000 after acquiring an additional 625,817 shares in the last quarter. Jane Street Group LLC increased its position in shares of Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after acquiring an additional 91,222 shares in the last quarter. Finally, Armistice Capital LLC increased its position in shares of Autolus Therapeutics by 19.6% in the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after acquiring an additional 1,800,000 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Further Reading

Should You Invest $1,000 in Autolus Therapeutics Right Now?

Before you consider Autolus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.

While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines